James Campbell, DO
Internal Medicine · Norton, VANPI 1629128640
Payments from drug & device makers
Across 152 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$317
- Amarin Pharma, Inc.$221
- Johnson & Johnson$218
- AstraZeneca$154
- Amgen$148
- Exact Sciences$145
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $317 |
| Amarin Pharma, Inc. | 13 | $221 |
| Johnson & Johnson(2 entities) | 13 | $218 |
| AstraZeneca | 11 | $154 |
| Amgen(2 entities) | 9 | $148 |
| Exact Sciences | 7 | $145 |
| AbbVie(2 entities) | 9 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $140 |
| Corium, LLC | 6 | $139 |
| GSK | 6 | $110 |
| Lilly USA, LLC | 6 | $107 |
| Lundbeck LLC | 6 | $102 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Pfizer | 6 | $90 |
| Novartis | 4 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $60 |
| Bayer | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $11 |
How this compares
$2,566 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $105,448 |
| EliquisApixaban | 135 | $105,400 |
| JanuviaSitagliptin Phosphate | 90 | $79,480 |
| FarxigaDapagliflozin Propanediol | 75 | $63,743 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 77 | $48,132 |
| MounjaroTirzepatide | 39 | $41,319 |
| XareltoRivaroxaban | 22 | $23,177 |
| RybelsusSemaglutide | 19 | $22,694 |
| JardianceEmpagliflozin | 27 | $22,310 |
| TrulicityDulaglutide | 15 | $21,440 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $20,852 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $19,097 |
| Repatha SyringeEvolocumab | 23 | $18,663 |
| LinzessLinaclotide | 34 | $17,947 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $17,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $317 | $128,142114 claims |
| PfizerEliquis, Dilantin | $90 | $109,966166 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $154 | $93,607129 claims |
| Lilly USA, LLCMounjaro, Trulicity | $107 | $62,75954 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $100 | $48,13277 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $16 | $29,69842 claims |
| Johnson & JohnsonXarelto | $218 | $23,17722 claims |
| AbbVieLinzess, Synthroid | $145 | $20,93280 claims |
| NovartisEntresto | $63 | $8,76613 claims |
| GSKShingrix | $110 | $2,58012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Norton
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.